Wook-Je Cho (L), CEO of Yuhan Corporation, and Anna Jo, CEO of J INTS BIO
May 31, 2023 03:17 PM EDT
Deals
Pharma

Yuhan Cor­po­ra­tion to pay $325M to in-li­cense pre­clin­i­cal HER2 can­di­date

Paul Schloesser

Associate Editor

Yuhan Cor­po­ra­tion said Tues­day that it is pay­ing up to $325 mil­lion to fel­low South Ko­re­an biotech J INTS Bio to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times